Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics

Xinyu Fang, Yewei Wang, Yan Chen, Juanjuan Ren, Chen ZhangSchizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of ChinaObjective: Second-generation antipsychotics (SGAs) have a high risk of causing metabolic syn...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fang X, Wang Y, Chen Y, Ren J, Zhang C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	schizophrenia interleukin-6 metabolic syndrome second-generation antipsychotics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c54246123f494991abd380a82d508820
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c54246123f494991abd380a82d508820
record_format	dspace
spelling	oai:doaj.org-article:c54246123f494991abd380a82d5088202021-12-02T06:30:20ZAssociation between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics1178-2021https://doaj.org/article/c54246123f494991abd380a82d5088202019-07-01T00:00:00Zhttps://www.dovepress.com/association-between-il-6-and-metabolic-syndrome-in-schizophrenia-patie-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Xinyu Fang, Yewei Wang, Yan Chen, Juanjuan Ren, Chen ZhangSchizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of ChinaObjective: Second-generation antipsychotics (SGAs) have a high risk of causing metabolic syndrome (MetS). There is accumulating evidence supporting the fact that the activation of inflammatory pathway contributes to the development of MetS and further aggravates cognitive impairment. This study aimed to investigate the relationship between interleukin-6 (IL-6), cognitive function, and MetS in schizophrenia patients treated with SGAs.Methods: One hundred and seventy-four patients with schizophrenia using SGAs were divided into MetS and non-MetS group, based on the criteria of the National Cholesterol Education Program’s Adult Treatment Panel III. Cognitive function was measured using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). A total of 138 patients and 29 healthy controls were examined in the plasma IL-6 levels.Results: The prevalence of MetS in schizophrenia patients treated with SGAs was 33% in this study. There were no significant differences in cognitive functions (both RBANS total score and subscale score) between MetS and non-Mets patients (P>0.05). Patients with MetS had higher plasma levels of IL-6 compared to non-MetS patients (P=0.019). However, such difference was only found in male patients (male: P=0.012; female: P=0.513). The partial correlational analysis further showed that IL-6 levels were notably negative related to the HDL levels in male schizophrenia patients after age, years of education, body mass index (BMI), age of onset, total disease course, and equal dose of olanzapine were controlled (male: P=0.009; female: P=0.450). In addition, the multiple regression analysis (stepwise model) performed in the male patient subgroup showed that IL-6 (beta =−0.283, t=−2.492, P=0.015) was an independent contributor to the HDL levels. However, the IL-6 was not an independent contributor to the HDL levels in female patients.Conclusion: Our findings provide evidence suggesting that the immune-inflammatory effect of IL-6 on SGAs-induced MetS may be in a gender manner.Keywords: schizophrenia, interleukin-6, metabolic syndrome, second-generation antipsychoticsFang XWang YChen YRen JZhang CDove Medical Pressarticleschizophreniainterleukin-6metabolic syndromesecond-generation antipsychoticsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 2161-2170 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	schizophrenia interleukin-6 metabolic syndrome second-generation antipsychotics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	schizophrenia interleukin-6 metabolic syndrome second-generation antipsychotics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Fang X Wang Y Chen Y Ren J Zhang C Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
description	Xinyu Fang, Yewei Wang, Yan Chen, Juanjuan Ren, Chen ZhangSchizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of ChinaObjective: Second-generation antipsychotics (SGAs) have a high risk of causing metabolic syndrome (MetS). There is accumulating evidence supporting the fact that the activation of inflammatory pathway contributes to the development of MetS and further aggravates cognitive impairment. This study aimed to investigate the relationship between interleukin-6 (IL-6), cognitive function, and MetS in schizophrenia patients treated with SGAs.Methods: One hundred and seventy-four patients with schizophrenia using SGAs were divided into MetS and non-MetS group, based on the criteria of the National Cholesterol Education Program’s Adult Treatment Panel III. Cognitive function was measured using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). A total of 138 patients and 29 healthy controls were examined in the plasma IL-6 levels.Results: The prevalence of MetS in schizophrenia patients treated with SGAs was 33% in this study. There were no significant differences in cognitive functions (both RBANS total score and subscale score) between MetS and non-Mets patients (P>0.05). Patients with MetS had higher plasma levels of IL-6 compared to non-MetS patients (P=0.019). However, such difference was only found in male patients (male: P=0.012; female: P=0.513). The partial correlational analysis further showed that IL-6 levels were notably negative related to the HDL levels in male schizophrenia patients after age, years of education, body mass index (BMI), age of onset, total disease course, and equal dose of olanzapine were controlled (male: P=0.009; female: P=0.450). In addition, the multiple regression analysis (stepwise model) performed in the male patient subgroup showed that IL-6 (beta =−0.283, t=−2.492, P=0.015) was an independent contributor to the HDL levels. However, the IL-6 was not an independent contributor to the HDL levels in female patients.Conclusion: Our findings provide evidence suggesting that the immune-inflammatory effect of IL-6 on SGAs-induced MetS may be in a gender manner.Keywords: schizophrenia, interleukin-6, metabolic syndrome, second-generation antipsychotics
format	article
author	Fang X Wang Y Chen Y Ren J Zhang C
author_facet	Fang X Wang Y Chen Y Ren J Zhang C
author_sort	Fang X
title	Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
title_short	Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
title_full	Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
title_fullStr	Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
title_full_unstemmed	Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
title_sort	association between il-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/c54246123f494991abd380a82d508820
work_keys_str_mv	AT fangx associationbetweenil6andmetabolicsyndromeinschizophreniapatientstreatedwithsecondgenerationantipsychotics AT wangy associationbetweenil6andmetabolicsyndromeinschizophreniapatientstreatedwithsecondgenerationantipsychotics AT cheny associationbetweenil6andmetabolicsyndromeinschizophreniapatientstreatedwithsecondgenerationantipsychotics AT renj associationbetweenil6andmetabolicsyndromeinschizophreniapatientstreatedwithsecondgenerationantipsychotics AT zhangc associationbetweenil6andmetabolicsyndromeinschizophreniapatientstreatedwithsecondgenerationantipsychotics
_version_	1718399898985955328

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics

Ejemplares similares